Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
ID: 347224Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347224

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-148.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment. This initiative seeks applications for epidemiological and observational studies that investigate adverse outcomes and morbidity associated with post-TB lung disease, particularly in both adult and pediatric populations, with a focus on individuals affected by HIV. Understanding the implications of post-TB lung disease is crucial for improving healthcare strategies and patient management for TB survivors. Interested applicants can find more information and submission guidelines at the NIH website, with applications due by May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-148-Full-Announcement.html
    PAR-23-148.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a Notice of Funding Opportunity (NOFO) titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)." This initiative aims to fund research that explores the long-term cardiopulmonary effects of tuberculosis (TB) treatment, emphasizing studies on both adult and pediatric cohorts, particularly regarding adverse outcomes related to post-TB lung disease (PTLD). Research proposals should focus on understanding the epidemiology, clinical manifestations, and biological mechanisms of PTLD, with an emphasis on individuals affected by HIV. Eligible applicants include higher education institutions, nonprofits, and government agencies, among others. The funding period can extend up to five years, with no budget limitations provided they reflect the project's actual needs. Applications for this grant must adhere strictly to NIH submission guidelines and are due by scheduled deadlines, with a primary goal of reducing the burden of long-term morbidity from TB. Understanding PTLD's impact on healthcare can inform better patient management and treatment strategies, ultimately improving health outcomes for TB survivors.
    Similar Opportunities
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt)" aimed at supporting the development of long-acting/sustained release (LA/SR) technologies for the prevention and treatment of HIV and associated co-infections such as tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). This initiative seeks to fund preclinical activities that will advance these technologies toward submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA), with a focus on ensuring safety and efficacy through rigorous studies. The program is particularly significant as it addresses public health challenges related to infectious diseases that disproportionately affect individuals living with HIV, and it will provide approximately $4 million to support 3-5 awards, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses" (R21 - Clinical Trial Optional) aimed at supporting research into the neurological and mental health outcomes associated with chronic illnesses linked to infections, including the post-acute sequelae of COVID-19 (Neuro-PASC). The initiative encourages applications that investigate the mechanisms underlying these conditions, with a particular interest in studies that explore common pathophysiologies across various infection-associated chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and postural orthostatic tachycardia syndrome (POTS). Eligible applicants include a wide range of organizations, including higher education institutions and nonprofits, with a maximum funding amount of $275,000 available for a two-year project period. Applications are due by 5:00 PM local time on November 16, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)." This initiative invites applications that focus on the neurological and mental health manifestations associated with chronic illnesses resulting from infections, particularly the post-acute sequelae of COVID-19 (Neuro-PASC) and other conditions with potential infectious triggers. The funding aims to advance research into the mechanisms underlying these conditions, including neuroinflammation and brain dysfunction, with an emphasis on stakeholder engagement from underserved populations. Applications are due by November 6, 2025, with budgets capped at $500,000 annually and project durations of up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01), which invites researchers to apply for access to valuable biospecimens collected from an ongoing longitudinal study focused on tobacco use behaviors and health outcomes in the U.S. This initiative primarily provides urine, plasma, serum, and genomic DNA samples to support research relevant to tobacco regulations under the Family Smoking Prevention and Tobacco Control Act. The PATH Study, launched in 2011, plays a crucial role in advancing scientific understanding of tobacco use and its implications for public health. Applications will open on March 30, 2024, and close on October 31, 2026, with evaluations based on alignment with PATH objectives and the merit of proposed research. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R21 Clinical Trial Not Allowed)" aimed at investigating the mechanisms by which T-cells contribute to HIV's neurological implications. This initiative seeks to enhance understanding of HIV's seeding and persistence in the central nervous system (CNS), as well as its associated neurological disorders, encouraging research that explores T-cell neuro-invasion and potential therapeutic strategies. The total funding available is $5.5 million, with individual budgets capped at $275,000 over a two-year period, and applications are encouraged from a diverse range of eligible organizations, including higher education institutions and non-profits. Interested applicants should note that the submission deadline is March 18, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for further details.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.